GCP
BEAM icon

Gill Capital Partners’s Beam Therapeutics BEAM Stock Holding History

Gill Capital Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$515 Hold
15
– – ﹤0.01% 640
2026
Q1 		$357 Buy
+15
New +$416 ﹤0.01% 647

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Gill Capital Partners's BEAM Position: Q2 2026 in Review

Gill Capital Partners held its Beam Therapeutics (BEAM) position steady in Q2 2026 at 15 shares worth $515. The position accounts for ﹤0.01% of the portfolio, ranked #640.

Gill Capital Partners first reported a position in BEAM in Q1 2026 and has held it in 2 quarters since. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Gill Capital Partners held 15 shares of Beam Therapeutics worth $515 as of Q2 2026.
  • Gill Capital Partners left its Beam Therapeutics share count unchanged in Q2 2026.
  • Beam Therapeutics made up ﹤0.01% of Gill Capital Partners's portfolio in Q2 2026, its #640 holding.
  • Gill Capital Partners first reported a position in Beam Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Gill Capital Partners's 13F filing for Q2 2026, filed 20 Aug 2026.